Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

1Q Earnings Preview: What To Expect From US, EU Big Hitters

Executive Summary

The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.

Advertisement

Related Content

Court Probes Rationale Of Biosimilars' 180-Day Notice
'Transformative' Dupilumab Set For Third Quarter Filing In Atopic Dermatitis
FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx
Lilly's Leap Tests Investors' Faith In Solanezumab
Amgen Mum On Repatha Sales; Outcomes Data Needed To Sway US Payers
Sanofi Files LixiLan For Diabetes, Gambles Expensive Priority Review Voucher
Lantus Follow-On Basaglar OK'd, But Can Lilly Sell It?
Repatha OK'd; Payers Eye PCSK9 Rebate/Discount War
Sanofi paying big for FDA voucher; Retrophin snags $245m
Lilly sets timelines for solanezumab

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel